EQS-Adhoc

Kuros Biosciences AG: valuationLAB Initiates Research Coverage on Kuros - Seite 2

additional funds will be needed to bring KUR-111 and KUR-113 successfully
to market. To finance the significant R&D costs until 2023, it is expected
that Kuros will out license KUR-023 to a commercialization partner upon EU
approval and both orthobiologics on successful pivotal trials in return for
significant upfront, development and sales milestone payments and royalties
on sales.

Upcoming milestones and key catalysts in valuationLAB's report include 1)
the filing of CE marking for KUR-023 around year-end 2016 followed by
approval and launch in the EU in 2017; 2) the start of a clinical trial in
2017 to support the PMA of KUR-023 for application in the US; and 3) the
signing of distribution or commercialization agreements in the EU.

Harry Welten, Chief Financial Officer of Kuros, commented: "We believe this
analyst report provides useful guidance to the investment community on the
Kuros investment case as we execute on our strategy to advance the lead
candidates and unlock the value of the pipeline for our shareholders. We
endeavor to become a future leader in tissue repair and regeneration."

The full analyst research report is available from www.valuationlab.com and
Kuros' website www.kuros.ch under Investors/Reports & presentations.

About valuationLAB

valuationLAB AG is an independent life science research boutique with no
securities or banking services. The company does not hold any positions in
the securities mentioned in its reports. Its financial analyses are based
on the Directives on the Independence of Financial Research issued by the
Swiss Bankers Association in January 2008. valuationLAB's aim is to
translate complicated scientific/clinical data into easy-to-understand
financial forecasts and valuations for investors. Valuations are based on
tailor-made, detailed, bottom-up research from publicly available sources.
The research report has been commissioned by Kuros Biosciences AG and
prepared and issued by valuationLAB AG. The analyst views and expectations
were made independently and as such do not necessarily reflect those of
Kuros.

For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: [phone]
[e-mail]

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products
for tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the International Financial
Reporting Standard on the SIX Swiss Exchange Ltd under the symbol KURN.